BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 36279295)

  • 1. Variant APOL1 protein in plasma associates with larger particles in humans and mouse models of kidney injury.
    Andrews M; Yoshida T; Henderson CM; Pflaum H; McGregor A; Lieberman JA; de Boer IH; Vaisar T; Himmelfarb J; Kestenbaum B; Chung JY; Hewitt SM; Santo BA; Ginley B; Sarder P; Rosenberg AZ; Murakami T; Kopp JB; Kuklenyik Z; Hoofnagle AN
    PLoS One; 2022; 17(10):e0276649. PubMed ID: 36279295
    [TBL] [Abstract][Full Text] [Related]  

  • 2. APOL1-G0 protects podocytes in a mouse model of HIV-associated nephropathy.
    Bruggeman LA; Wu Z; Luo L; Madhavan S; Drawz PE; Thomas DB; Barisoni L; O'Toole JF; Sedor JR
    PLoS One; 2019; 14(10):e0224408. PubMed ID: 31661509
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mechanisms of Injury in APOL1-associated Kidney Disease.
    Ma L; Divers J; Freedman BI
    Transplantation; 2019 Mar; 103(3):487-492. PubMed ID: 30371607
    [TBL] [Abstract][Full Text] [Related]  

  • 4. APOL1 renal risk variants exacerbate podocyte injury by increasing inflammatory stress.
    Wakashin H; Heymann J; Roshanravan H; Daneshpajouhnejad P; Rosenberg A; Shin MK; Hoek M; Kopp JB
    BMC Nephrol; 2020 Aug; 21(1):371. PubMed ID: 32854642
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hypoxia hits APOL1 in the kidney.
    Grampp S; Krüger R; Lauer V; Uebel S; Knaup KX; Naas J; Höffken V; Weide T; Schiffer M; Naas S; Schödel J
    Kidney Int; 2023 Jul; 104(1):53-60. PubMed ID: 37098381
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Transgenic expression of human APOL1 risk variants in podocytes induces kidney disease in mice.
    Beckerman P; Bi-Karchin J; Park AS; Qiu C; Dummer PD; Soomro I; Boustany-Kari CM; Pullen SS; Miner JH; Hu CA; Rohacs T; Inoue K; Ishibe S; Saleem MA; Palmer MB; Cuervo AM; Kopp JB; Susztak K
    Nat Med; 2017 Apr; 23(4):429-438. PubMed ID: 28218918
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antisense oligonucleotides ameliorate kidney dysfunction in podocyte-specific APOL1 risk variant mice.
    Yang YW; Poudel B; Frederick J; Dhillon P; Shrestha R; Ma Z; Wu J; Okamoto K; Kopp JB; Booten SL; Gattis D; Watt AT; Palmer M; Aghajan M; Susztak K
    Mol Ther; 2022 Jul; 30(7):2491-2504. PubMed ID: 35450819
    [TBL] [Abstract][Full Text] [Related]  

  • 8. APOL1 risk variants cause podocytes injury through enhancing endoplasmic reticulum stress.
    Wen H; Kumar V; Lan X; Shoshtari SSM; Eng JM; Zhou X; Wang F; Wang H; Skorecki K; Xing G; Wu G; Luo H; Malhotra A; Singhal PC
    Biosci Rep; 2018 Aug; 38(4):. PubMed ID: 29967295
    [TBL] [Abstract][Full Text] [Related]  

  • 9. APOL1-G0 or APOL1-G2 Transgenic Models Develop Preeclampsia but Not Kidney Disease.
    Bruggeman LA; Wu Z; Luo L; Madhavan SM; Konieczkowski M; Drawz PE; Thomas DB; Barisoni L; Sedor JR; O'Toole JF
    J Am Soc Nephrol; 2016 Dec; 27(12):3600-3610. PubMed ID: 27026370
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Cell Biology of APOL1.
    O'Toole JF; Bruggeman LA; Madhavan S; Sedor JR
    Semin Nephrol; 2017 Nov; 37(6):538-545. PubMed ID: 29110761
    [TBL] [Abstract][Full Text] [Related]  

  • 11. APOL1 polymorphisms and kidney disease: loss-of-function or gain-of-function?
    Bruggeman LA; O'Toole JF; Sedor JR
    Am J Physiol Renal Physiol; 2019 Jan; 316(1):F1-F8. PubMed ID: 30332315
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A tripartite complex of suPAR, APOL1 risk variants and α
    Hayek SS; Koh KH; Grams ME; Wei C; Ko YA; Li J; Samelko B; Lee H; Dande RR; Lee HW; Hahm E; Peev V; Tracy M; Tardi NJ; Gupta V; Altintas MM; Garborcauskas G; Stojanovic N; Winkler CA; Lipkowitz MS; Tin A; Inker LA; Levey AS; Zeier M; Freedman BI; Kopp JB; Skorecki K; Coresh J; Quyyumi AA; Sever S; Reiser J
    Nat Med; 2017 Aug; 23(8):945-953. PubMed ID: 28650456
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The evolving story of apolipoprotein L1 nephropathy: the end of the beginning.
    Daneshpajouhnejad P; Kopp JB; Winkler CA; Rosenberg AZ
    Nat Rev Nephrol; 2022 May; 18(5):307-320. PubMed ID: 35217848
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Apolipoprotein L1 Gene and Cardiovascular Disease.
    Robinson TW; Freedman BI
    Methodist Debakey Cardiovasc J; 2016; 12(4 Suppl):2-5. PubMed ID: 28298955
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recruitment of APOL1 kidney disease risk variants to lipid droplets attenuates cell toxicity.
    Chun J; Zhang JY; Wilkins MS; Subramanian B; Riella C; Magraner JM; Alper SL; Friedman DJ; Pollak MR
    Proc Natl Acad Sci U S A; 2019 Feb; 116(9):3712-3721. PubMed ID: 30733285
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genetic Inhibition of APOL1 Pore-Forming Function Prevents APOL1-Mediated Kidney Disease.
    Hung AM; Assimon VA; Chen HC; Yu Z; Vlasschaert C; Triozzi JL; Chan H; Wheless L; Wilson O; Shah SC; Mack T; Thompson T; Matheny ME; Chandrasekar S; Mozaffari SV; Chung CP; Tsao P; Susztak K; Siew ED; Estrada K; Gaziano JM; Graham RR; Tao R; Hoek M; Robinson-Cohen C; Green EM; Bick AG;
    J Am Soc Nephrol; 2023 Nov; 34(11):1889-1899. PubMed ID: 37798822
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An Acidic Environment Induces APOL1-Associated Mitochondrial Fragmentation.
    Li D; Snipes JA; Murea M; Molina AJA; Divers J; Freedman BI; Ma L; Petrovic S
    Am J Nephrol; 2020; 51(9):695-704. PubMed ID: 32866949
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recessive, gain-of-function toxicity in an APOL1 BAC transgenic mouse model mirrors human APOL1 kidney disease.
    McCarthy GM; Blasio A; Donovan OG; Schaller LB; Bock-Hughes A; Magraner JM; Suh JH; Tattersfield CF; Stillman IE; Shah SS; Zsengeller ZK; Subramanian B; Friedman DJ; Pollak MR
    Dis Model Mech; 2021 Aug; 14(8):. PubMed ID: 34350953
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel Human Podocyte Cell Model Carrying G2/G2 APOL1 High-Risk Genotype.
    Ekulu PM; Adebayo OC; Decuypere JP; Bellucci L; Elmonem MA; Nkoy AB; Mekahli D; Bussolati B; van den Heuvel LP; Arcolino FO; Levtchenko EN
    Cells; 2021 Jul; 10(8):. PubMed ID: 34440683
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Apolipoprotein L1 (APOL1) cation current in HEK-293 cells and in human podocytes.
    Vandorpe DH; Heneghan JF; Waitzman JS; McCarthy GM; Blasio A; Magraner JM; Donovan OG; Schaller LB; Shah SS; Subramanian B; Riella CV; Friedman DJ; Pollak MR; Alper SL
    Pflugers Arch; 2023 Mar; 475(3):323-341. PubMed ID: 36449077
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.